RecruitingNCT04347187

REGistry of Long-term AnTithrombotic TherApy-2

Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation

Sponsor

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Enrollment

2,000 participants

Start Date

Jan 15, 2015

Study Type

OBSERVATIONAL

Conditions

Atrial Fibrillation

Summary

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term registry study tracking patients with irregular heart rhythm (atrial fibrillation) who are taking blood-thinning medications. The goal is to understand real-world outcomes and treatment patterns for people on long-term anticoagulation therapy. **You may be eligible if:** - You have documented atrial fibrillation (an irregular heartbeat) - Your stroke risk score (called CHA2DS2-VASc) is greater than 1, meaning you are at elevated risk for stroke - You are willing and able to provide informed consent **You may NOT be eligible if:** - You had a heart attack (ACS) within the past 12 months - You have severe heart failure (NYHA Class IV — unable to do any activity without discomfort) - You had a stroke within the past 6 months - You have severe liver, muscle, or kidney disease - It is not possible to contact you or your family for follow-up after one year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.